AAVXF:OTCMKTS
Abivax SA
139,00 USD
0,00%
(0,00) 1D
9. srp, 09:30:01 GMT -4 · USD
search
Svi simboli
| Simbol | Cijena | Promjena | Postotna promjena |
|---|
insights_autoGeneriranje najvažnijih uvida za AAVXF...
Trž. kap.
6,75 mlr.
Prosj. kol.
0,00
Količina
0,00
52-tjed. najviša
139,00 USD
52-tjed. najniža
71,26 USD
Beta
3,09
Dionice u optjecaju
87,53 mil.
Broj djelatnika
98
Trž. kap.
6,75 mlr.
Prosj. kol.
0,00
Količina
0,00
52-tjed. najviša
139,00 USD
52-tjed. najniža
71,26 USD
Beta
3,09
Dionice u optjecaju
87,53 mil.
Broj djelatnika
98
Vijesti
Iz web-izvora i od partnera za vijesti
Idéal Investisseur
·
prije 17 sati
Abivax stock breaks below its 77.10 € support level despite Goldman Sachs buying recommendation
https://www.dars.gov.et/
·
prije 4 dana
ABVX Q2 2026 Earnings: Wider-Than-Expected Loss as Pre-Revenue Biotech Keeps Spending on Pipeline
Profil
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
Abivax SA – informacije
Glavni izvršni direktorMarc de Garidel | Hartmut J. Ehrlich
Zaposlenici98
Osnovano4. pro 2013.
Sjedište-
Sektor-
Web-lokacijaabivax.com